White Paper: Shortening the Rare Disease Diagnostic Odyssey

Specialty and rare diseases have undefined patient populations, with patients who are undiagnosed or misdiagnosed, healthcare providers who are unaware of disease states and their manifestations, as well as treatment journeys that are not well-understood. Shortening the Rare Disease Diagnostic Odyssey is filled with proven methodologies, specific use cases and diverse success stories on how pharmaceutical companies can identify, engage, and educate ideal patients who could benefit from innovative therapies and modalities of care.

IPM.ai is an Insights as a Service (IaaS) provider that empowers the world’s leading life sciences companies to better understand and improve the lives of patients through the development and commercialization of precision medicine for specialty and rare diseases. IPM’s system of insight streamlines market assessment, patient finding, treatment journey mapping, healthcare provider discovery, key opinion leader identification and brand activation by utilizing granular-level longitudinal analytics, artificial intelligence and machine learning in conjunction with a real world evidence, social determinants of health and outcomes research data universe of over 300 million de-identified patients.

Screen Shot 2021-03-27 at 4.14.39 PM

Request a Copy